Royalty Pharma plc remains a strong choice of stock for investors. Many are attracted to its potential, seeing it as a potentially
undervalued asset exhibiting strong financial resilience even amidst volatile market conditions. We've noted a growing trend of experts
selling or reducing their holdings, for instance,
Rehmann Capital Advisory Group and
AlTi Global Inc.. Nonetheless,
Cookson Peirce & Co.,
TD Asset Management Inc, and
Allianz Asset Management GmbH have increased their holdings.
Cullen Frost Bankers Inc and
Nordea Investment Management AB also increased their stock holdings. High-profile analysts, like
Goldman Sachs, initiated the stock with a Buy rating, pointing at a
20% potential upside. Furthermore, the company recently secured a hefty
$2B partnership with Revolution Medicines and committed
$300M to Zenas’ Obexelimab Program. This is underscored by a solid revenue growth and the declaration of a steady Q4 2025 dividend. Lastly, Royalty Pharma shows signs of
positive momentum and
strong support and resistance levels, which further solidifies its attractive growth profile.
Royalty Pharma Stocks News Analytics from Sun, 23 Feb 2025 08:00:00 GMT to Sun, 26 Oct 2025 01:10:45 GMT -
Rating 2
- Innovation 8
- Information 6
- Rumor -3
